StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Koselugo (selumetinib) — Worldwide product sales by Quarter

Koselugo (selumetinib) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Koselugo (selumetinib) — Worldwide product sales: $177M in Q2 2026, up 29.2% from a year earlier.

Latest, Q2 2026
177
Period ended Jun 30, 2026
Change on a year earlier
+29.2%
137 in Q2 2025
History
25 quarters
Since Q2 2020
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

“|| Koselugo | 177 | | 29 | | 27 | | 52 | | - | | 54 | | 51 | | 45 | | 50 | | 34 | | 27 | | 21 | | 78 | | 90”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKoselugo (selumetinib) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026177+29.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026170+23.2%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025163-1.2%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025224+88.2%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025137+20.2%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025138+4.5%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024165+94.1%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024119+36.8%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024114+42.5%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024132+67.1%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202385+46.6%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202387+81.3%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202380+29.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202379+102.6%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202258+70.6%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202248+84.6%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up koselugo (selumetinib) — Worldwide product sales

Cite this data

StockData. (2026). AstraZeneca Koselugo (selumetinib) — Worldwide product sales ($M), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-koselugo-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.